{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:33:51Z","timestamp":1780360431953,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1053\/j.semnuclmed.2017.09.007","type":"journal-article","created":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T13:01:10Z","timestamp":1506949270000},"page":"76-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["PET\/CT in Lymphoma: Current Overview and Future Directions"],"prefix":"10.1053","volume":"48","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0010","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0015","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"The role of imaging in the staging and response assessment of lymphoma: Consensus of the ICML Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0020","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0025","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0030","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2005.01.891","article-title":"Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET)","volume":"23","author":"Juweid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0035","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0040","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"PET-CT after front-line rituximab-chemotherapy is highly predictive of survival in follicular lymphoma: A pooled analysis of central scan review in three multi-centre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0045","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first International Workshop on Interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2017.09.007_bib0050","first-page":"139","article-title":"Follow-up of the 11-ICML workshop on lymphoma staging and restaging in the PET era","volume":"31","author":"Cheson","year":"2013","journal-title":"Haematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0055","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma\u2014The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0060","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for PET\/CT staged treatment naive Hodgkin lymphoma patients","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insights into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0070","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0075","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","article-title":"Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: A Danish-Swedish population-based study","volume":"33","author":"El-Galaly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0080","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin's lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0085","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0090","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0095","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood-2010-10-314260","article-title":"Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I\/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET","volume":"117","author":"Straus","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0100","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2017.09.007_bib0105","first-page":"163","article-title":"Interim PET-adapted chemotherapy in advanced Hodgkin lymphoma (HL). Results of the second interim analysis of the Italian GITIL\/FIL DH0607 trial","volume":"33","author":"Gallamini","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0110","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0115","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABC\u2009+\u2009VD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0120","doi-asserted-by":"crossref","first-page":"423404242","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0125","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.2013.53.2507","article-title":"The assessment of tumor size reduction improves outcome prediction of PET\/CT after chemotherapy in advanced stage Hodgkin lymphoma","volume":"32","author":"Kobe","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0130","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.578.578","article-title":"Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy\/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB\/Alliance 50604)","volume":"126","author":"Straus","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0135","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0140","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0145","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: Final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0150","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0155","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockage with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0165","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0170","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0175","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","article-title":"FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma","volume":"16","author":"Mikhaeel","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0180","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0185","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.110.082586","article-title":"18F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: Poor predictive value of international harmonization project interpretation","volume":"52","author":"Cashen","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0190","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2011-06-359943","article-title":"Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Pregno","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0195","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0200","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","article-title":"Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis","volume":"48","author":"Lin","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0210","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.3109\/10428194.2012.676173","article-title":"Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: Would using combined positron emission tomography and computed tomography criteria better predict response that each test alone?","volume":"53","author":"Kostakoglu","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0215","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","author":"Ceriani","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0220","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0225","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0235","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0240","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0245","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1158\/1078-0432.CCR-14-3128","article-title":"Immune-related response criteria\u2014Capturing clinical activity in immuno-oncology","volume":"21","author":"Hoos","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0250","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0255","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0260","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: A retrospective, European, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0265","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLLO5 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.007_bib0270","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","article-title":"Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLLO5 trial of the Fondazione Italiana Linfomi","volume":"101","author":"Luminari","year":"2016","journal-title":"Haematologica"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299817300843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299817300843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T15:43:07Z","timestamp":1603035787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299817300843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0001299817300843"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.007","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT in Lymphoma: Current Overview and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}